|Bid||0.0000 x 21500|
|Ask||0.0000 x 40000|
|Day's Range||1.5050 - 1.5500|
|52 Week Range||0.9500 - 2.1400|
|Beta (3Y Monthly)||2.30|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.80|
Geron Corporation (GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. “We are pleased to welcome Anil whose proven track record in shaping hematology-oncology development programs, launching blockbuster oncology products and managing external alliances rounds out our executive team’s capabilities,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on November 20, 2019 at an exercise price of $1.36 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.
Geron Corporation (GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The Company ended the third quarter with $159.3 million in cash and marketable securities. “Geron has continued to execute on its 2019 development plans,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.
MENLO PARK, Calif., Nov. 06, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that two abstracts related to imetelstat, the Company’s first-in-class telomerase.
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Corporation (GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call on Thursday, November 7 at 8:00 a.m. ET to discuss the financial results as well as recent events. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
Geron Corporation (GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “Patients with lower risk MDS become dependent on serial transfusions which leads to iron overload, heart and kidney complications, decreases in quality of life and shorter overall survival. Reducing transfusion burden and achieving transfusion independence remain significant medical needs for this disease,” said Aleksandra Rizo, M.D., Ph.D., Geron’s Chief Medical Officer.
Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.
Geron Corporation (GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the treatment of adult patients with Intermediate-2 or High-risk myelofibrosis (MF) whose disease has relapsed after or is refractory to janus kinase (JAK) inhibitor treatment, or relapsed/refractory MF. The Fast Track designation includes patients with primary MF and MF developed after essential thrombocythemia or polycythemia vera.
MENLO PARK, Calif., Sept. 26, 2019 -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to.
Chip Scarlett has been the CEO of Geron Corporation (NASDAQ:GERN) since 2011. This analysis aims first to contrast CEO...
Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.
Geron Corporation (GERN) today announced the opening of patient screening and enrollment for the Phase 3 portion of IMerge to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). “The start of the Phase 3 portion of IMerge is a significant milestone for Geron and imetelstat,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.